Drugline is a fortnightly electronic drug bulletin for health professionals.


Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

Longer Acting Paliperidone

Drugline Volume 452

A new presentation of paliperidone is now available on the Pharmaceutical Benefits Scheme (PBS). Invega Hafyera® is a six-monthly injection indicated for the maintenance treatment of adults with schizophrenia. Patients may be eligible for…

Read more

New Therapy for Systemic Lupus Erythematosus

Drugline Volume 451

Anifrolumab has recently been approved by the Therapeutic Goods Administration (TGA). It is indicated as an add-on to standard therapy for adult patients with moderate to severe active systemic lupus erythematosus (SLE). This chronic…

Read more

Indication Extension for Lenvatinib

Drugline Volume 450

The indications for lenvatinib have been extended. It is now indicated, in combination with pembrolizumab, for the first-line treatment of adults with advanced renal cell carcinoma. A phase 3 trial investigated the efficacy of…

Read more

Sepsis Clinical Care Standard

Drugline Volume 449

The Australian Commission on Safety and Quality in Health Care has launched Australia’s first standard of care for sepsis. Sepsis is a life-threatening condition that requires rapid treatment to reduce the risk of death…

Read more

Clarithromycin and Electrolyte Disturbances

Drugline Volume 448

A new contraindication has been added to the product information of Klacid® (clarithromycin). This product is now contraindicated in patients with hypomagnesaemia. Clarithromycin is a macrolide antibiotic indicated for the treatment and prevention of…

Read more

Clozapine Safety Advisory

Drugline Volume 447

The Therapeutic Goods Administration (TGA) has released a safety advisory regarding clozapine and the potential for severe gastrointestinal side effects. Additional warnings have been added to the product information (PI) and consumer medicine information…

Read more
Load More

August 2022

April 2022

February 2022

December 2021

November 2021

October 2021

August 2021

Post-injection Syndrome (Aug. 20 2021)

Alirocumab on the PBS (Aug. 06 2021)

May 2021

April 2021

PBS Changes for Adalimumab (Apr. 30 2021)

Short-course Oxycodone (Apr. 16 2021)

March 2021

January 2021

December 2020

November 2020

October 2020

September 2020

July 2020

May 2020

March 2020

December 2019

November 2019

October 2019

New Warning for Febuxostat (Oct. 18 2019)

Naloxone Nasal Spray (Oct. 04 2019)

April 2019

New High-Strength Insulin (Apr. 18 2019)

Tofacitinib Safety Issue (Apr. 05 2019)

March 2019

February 2019

January 2019